Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allergen labeling guidance

This article was originally published in The Tan Sheet

Executive Summary

"Is a major food allergen that has been unintentionally added to a food as a result of cross-contact subject to FALCPA's labeling requirements?" is a question FDA answers in the second edition of its industry guidance on the Food Allergen Labeling & Consumer Protection Act of 2004. According to the document, major food allergens that are "unintentionally" added to a food due to cross-contact are not subject to FALCPA labeling requirements. The agency first released the question-and-answer guidance in October and expects to issue new editions as more questions are posed by industry (1"The Tan Sheet" Oct. 24, 2005, p. 10). The deadline for FALCPA labeling compliance is Jan. 1...

You may also be interested in...

FDA Guidance Clarifies Labeling For Supplements Containing Food Allergens

Manufacturers of dietary supplements are required to begin labeling products that contain major food allergens on Jan. 1 in order to comply with the Food Allergen Labeling & Consumer Protection Act of 2004 (FALCPA)

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts